Along this line of reasoning, zoledronic acid, approved for the treatment of osteoporosis and bone metastasis and identified as a UGT8 inhibitor, reduced the tumorigenesis of basal-like breast cancer cells in vitro [30]. Here, UGT8 is linked to osteoporosis.